Cooper Companies (NASDAQ:COO) Releases Q4 2026 Earnings Guidance

Cooper Companies (NASDAQ:COO) updated its fourth quarter 2026 earnings guidance on Wednesday. The company provided EPS guidance of 1.050-1.090 for the period, compared to the consensus earnings per share estimate of 1.200. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Cooper Companies also updated its FY 2026 guidance to 4.510-4.550 EPS.

Cooper Companies Stock Down 6.2%

Shares of Cooper Companies stock traded down $4.21 during trading on Wednesday, hitting $63.48. 8,920,917 shares of the stock traded hands, compared to its average volume of 2,349,299. The stock has a market cap of $12.38 billion, a P/E ratio of 53.80, a PEG ratio of 1.82 and a beta of 0.82. The company has a fifty day moving average price of $72.59 and a two-hundred day moving average price of $70.17. Cooper Companies has a twelve month low of $58.89 and a twelve month high of $89.83. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities research analysts predict that Cooper Companies will post 4.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

COO has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a report on Sunday, June 21st. Needham & Company LLC reduced their price target on Cooper Companies from $101.00 to $86.00 and set a “buy” rating for the company in a research report on Friday, June 5th. Robert W. Baird decreased their price target on Cooper Companies from $98.00 to $85.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Citigroup reissued a “neutral” rating and issued a $80.00 price objective (up from $76.00) on shares of Cooper Companies in a research note on Thursday, August 13th. Finally, Mizuho set a $85.00 target price on Cooper Companies and gave the stock an “outperform” rating in a report on Thursday, June 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $81.64.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies increased its share-repurchase authorization from $2 billion to $3 billion. The larger buyback could support earnings per share and signal that management views the stock as undervalued. The company also said its board remains open to other value-creation options. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: CooperCompanies completed its strategic review and unanimously decided to retain CooperSurgical. While the decision removes uncertainty around the business, it also means the company will not receive a potential near-term cash infusion from a sale or separation. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: The company released fiscal third-quarter 2026 results for the period ended July 31. The supplied announcement does not include the reported revenue or earnings figures, so the market’s reaction is likely being driven primarily by the forward guidance. CooperCompanies Announces Third Quarter 2026 Results
• Negative Sentiment: Fiscal 2026 adjusted EPS guidance of $4.51–$4.55 is below the consensus estimate of $4.63. Revenue guidance of $4.2–$4.3 billion is also below or only reaches the $4.3 billion consensus at the high end, suggesting weaker-than-expected growth or profitability.
• Negative Sentiment: Fourth-quarter 2026 EPS guidance of $1.05–$1.09 is well below the $1.20 consensus estimate. Although revenue guidance of approximately $1.1 billion is broadly in line with expectations, the earnings shortfall indicates pressure on margins, costs, or the business mix.

Institutional Trading of Cooper Companies

Institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Cooper Companies by 48.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock worth $1,890,000 after purchasing an additional 7,363 shares during the period. First Trust Advisors LP raised its stake in shares of Cooper Companies by 115.8% in the 2nd quarter. First Trust Advisors LP now owns 136,334 shares of the medical device company’s stock valued at $9,702,000 after buying an additional 73,165 shares in the last quarter. Cresset Asset Management LLC bought a new position in shares of Cooper Companies during the 2nd quarter worth about $291,000. Cerity Partners LLC boosted its position in shares of Cooper Companies by 4.4% during the 2nd quarter. Cerity Partners LLC now owns 17,870 shares of the medical device company’s stock valued at $1,272,000 after acquiring an additional 757 shares in the last quarter. Finally, Daiwa Securities Group Inc. increased its stake in Cooper Companies by 2.8% in the second quarter. Daiwa Securities Group Inc. now owns 35,839 shares of the medical device company’s stock valued at $2,551,000 after acquiring an additional 973 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.